Published by Coherent Market Insights
Posted on September 14, 2021
Antibody drug conjugate (ADC) is a class of biopharmaceutical drugs indicated as a targeted therapy for treating cancer. ADC is are designed to kill only cancer cells and spare healthy cells, which makes it more effective than traditional cancer treatment options such as chemotherapy. They are compounds of molecules consisting antibodies associated with biologically active cytotoxic drug.
By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/181
Market Dynamics- Drivers
Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market
Growing approval for ADCs in the recent past is expected to drive growth of the global antibody drug conjugates market during the forecast period. In terms of marketing, three antibody drug conjugates have received regulatory approval. In 2001, an ADC developed by Pfizer/Wyeth received the U.S. Food and Drug Administration (FDA) approval, which was indicated to treat acute myelogenous leukemia. However, the drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The other two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Furthermore, there are around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. There are several cytotoxins used for development of antibody drug conjugates under trials such as auristatin, calicheamicin, maytansine, and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Moreover, Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins. Thus, marketing and research and development regarding ADCs are expected to drive growth of the global antibody drug conjugates market over the forecast period.
Global antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the market to two digit billion dollar mark by 2020
The global antibody drug conjugates market is segmented on the basis of drug and geography. On the basis of drug, the market is divided into Adcetris and Kadcyla.
Regional Outlook
Major pharmaceutical company opt for contract manufacturer for development and manufacture of antibody drug conjugates
Regional segmentation of the antibody drug conjugates market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Among regions, Europe accounts for the largest share in the global market, owing to presence of many contract manufacturing companies with advanced manufacturing equipment. Lonza, a Switzerland based company, is one of the top contract manufacturing companies in Europe, which has operations across France and Germany. One of the facilities operated by the company is a deck to chemical manufacturing capabilities and develop peptides, small molecule active pharmaceutical ingredients, highly potent active pharmaceutical ingredients, cytotoxics agents, antibody drug conjugates, and microbial products. The company also offer proficiency in chemical, pharmaceutical, agrochemical and food industries by providing clients with yields such as high-class active substances, organic chemicals and intermediates.
Major companies in the global antibody drug conjugates market are involved in research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the global antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future.
Key Developments
Major companies in the market are focused on various growth strategies such as gaining product approval from regulatory authorities, in order to expand their product portfolio. For instance, in June 2019, Roche Holding AG, a Switzerland-based healthcare company, received the U.S. Food and Drug Administration (FDA) approval for Polivy, which is an antibody-drug conjugate. Polivy is used for patients suffering from advanced lymphoma.
Key companies in the market are involved in various business strategies such as research and development in order to enhance the global market presence. For instance, in June 2019, Seattle Genetics and Astellas Pharma, Inc. announced the date from first cohort of pivotal phase 2 clinical trial called EV-201. It demonstrated that the investigational agent enfortubmab vedotin, an antibody-drug conjugate, rapidly shrunk the tumor in most patients.
Major players in the market are involved in different growth strategies such as partnership and collaboration, in order to develop novel products and gain competitive edge in the market. For instance, in March 2019, LegoChem Biosciences and Takeda entered into research collaboration and license agreement to develop an antibody-drug conjugate. This conjugate will be used in immune-oncology.
Top Key Players Include In Antibody Drug Conjugates Market: Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc., Pfizer Inc., Sanofi, AbbVie Inc., Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/181
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Antibody Drug Conjugates Market: Research and Development Activities to Open Up New Avenues appeared first on Gatorledger.
Antibody drug conjugate (ADC) is a class of biopharmaceutical drugs indicated as a targeted therapy for treating cancer. ADC is are designed to kill only cancer cells and spare healthy cells, which makes it more effective than traditional cancer treatment options such as chemotherapy. They are compounds of molecules consisting antibodies associated with biologically active cytotoxic drug.
By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.
Click Here To Get Sample Copy @ https://www.coherentmarketinsights.com/insight/request-sample/181
Market Dynamics- Drivers
Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market
Growing approval for ADCs in the recent past is expected to drive growth of the global antibody drug conjugates market during the forecast period. In terms of marketing, three antibody drug conjugates have received regulatory approval. In 2001, an ADC developed by Pfizer/Wyeth received the U.S. Food and Drug Administration (FDA) approval, which was indicated to treat acute myelogenous leukemia. However, the drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The other two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Furthermore, there are around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. There are several cytotoxins used for development of antibody drug conjugates under trials such as auristatin, calicheamicin, maytansine, and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Moreover, Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins. Thus, marketing and research and development regarding ADCs are expected to drive growth of the global antibody drug conjugates market over the forecast period.
Global antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the market to two digit billion dollar mark by 2020
The global antibody drug conjugates market is segmented on the basis of drug and geography. On the basis of drug, the market is divided into Adcetris and Kadcyla.
Regional Outlook
Major pharmaceutical company opt for contract manufacturer for development and manufacture of antibody drug conjugates
Regional segmentation of the antibody drug conjugates market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Among regions, Europe accounts for the largest share in the global market, owing to presence of many contract manufacturing companies with advanced manufacturing equipment. Lonza, a Switzerland based company, is one of the top contract manufacturing companies in Europe, which has operations across France and Germany. One of the facilities operated by the company is a deck to chemical manufacturing capabilities and develop peptides, small molecule active pharmaceutical ingredients, highly potent active pharmaceutical ingredients, cytotoxics agents, antibody drug conjugates, and microbial products. The company also offer proficiency in chemical, pharmaceutical, agrochemical and food industries by providing clients with yields such as high-class active substances, organic chemicals and intermediates.
Major companies in the global antibody drug conjugates market are involved in research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the global antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future.
Key Developments
Major companies in the market are focused on various growth strategies such as gaining product approval from regulatory authorities, in order to expand their product portfolio. For instance, in June 2019, Roche Holding AG, a Switzerland-based healthcare company, received the U.S. Food and Drug Administration (FDA) approval for Polivy, which is an antibody-drug conjugate. Polivy is used for patients suffering from advanced lymphoma.
Key companies in the market are involved in various business strategies such as research and development in order to enhance the global market presence. For instance, in June 2019, Seattle Genetics and Astellas Pharma, Inc. announced the date from first cohort of pivotal phase 2 clinical trial called EV-201. It demonstrated that the investigational agent enfortubmab vedotin, an antibody-drug conjugate, rapidly shrunk the tumor in most patients.
Major players in the market are involved in different growth strategies such as partnership and collaboration, in order to develop novel products and gain competitive edge in the market. For instance, in March 2019, LegoChem Biosciences and Takeda entered into research collaboration and license agreement to develop an antibody-drug conjugate. This conjugate will be used in immune-oncology.
Top Key Players Include In Antibody Drug Conjugates Market: Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc., Pfizer Inc., Sanofi, AbbVie Inc., Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals.
Get This premium report with Instant US$ 2000 discount @ https://www.coherentmarketinsights.com/promo/buynow/181
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027
Email: sales@coherentmarketinsights.com
The post Antibody Drug Conjugates Market: Research and Development Activities to Open Up New Avenues appeared first on Gatorledger.
Explore more articles in the Research Reports category
